相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations
Fang Hu et al.
CLINICAL LUNG CANCER (2019)
Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer (vol 8, e020690, 2018)
John Conibear et al.
BMJ OPEN (2019)
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer A Phase 2 Randomized Clinical Trial
Puneeth Iyengar et al.
JAMA ONCOLOGY (2018)
Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450)
Dirk De Ruysscher et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Stereotactic Ablative Radiation Therapy for the Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): Results of a Randomized Trial
D. A. Palma et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Stereotactic Ablative Radiation Therapy for Pulmonary Metastases: Histology, Dose, and Indication Matter
Joelle Helou et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases: An International Survey of >1000 Radiation Oncologists
Stephen L. Lewis et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2017)
The Eighth Edition Lung Cancer Stage Classification
Frank C. Detterbeck et al.
CHEST (2017)
Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases
Nataniel H. Lester-Coll et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Fabrice Barlesi et al.
LANCET (2016)
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
Daniel R. Gomez et al.
LANCET ONCOLOGY (2016)
Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients
M. Hecht et al.
ANNALS OF ONCOLOGY (2015)
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
Joe Y. Chang et al.
LANCET ONCOLOGY (2015)
Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients
C. Collen et al.
ANNALS OF ONCOLOGY (2014)
Esophageal Dose Tolerance to Hypofractionated Stereotactic Body Radiation Therapy: Risk Factors for Late Toxicity
Kevin L. Stephans et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Phase II Trial of Stereotactic Body Radiation Therapy Combined With Erlotinib for Patients With Limited but Progressive Metastatic Non-Small-Cell Lung Cancer
Puneeth Iyengar et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Stereotactic Ablative Radiotherapy for Pulmonary Oligometastases and Oligometastatic Lung Cancer
David Benjamin Shultz et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): Patient outcomes and prognostic factors
Gwendolyn H. M. J. Griffioen et al.
LUNG CANCER (2013)
Stereotactic body radiotherapy for multisite extracranial oligometastases Final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease
Joseph K. Salama et al.
CANCER (2012)
Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non-Small-Cell Lung Cancer
Andrew J. Weickhardt et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Oligometastatic Disease at Presentation or Recurrence for Nonsmall Cell Lung Cancer
Daniel R. Gomez et al.
PULMONARY MEDICINE (2012)
Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design
Jamie E. Chaft et al.
CLINICAL CANCER RESEARCH (2011)
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials - NSCLC meta-analyses collaborative group
S. Burdett et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Oligometastatic non-small cell lung cancer: A multidisciplinary approach in the positron emission tomographic scan era
Tommaso M. De Pas et al.
ANNALS OF THORACIC SURGERY (2007)
分享论文
